STEK (Stemtech) FCF Margin %: -92.01% (As of Mar. 2026)


What is Stemtech FCF Margin %?

Stemtech STEK FCF Margin % is -92.01% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Stemtech ranks worse than 71.29% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Stemtech's Free Cash Flow for the three months ended in Mar. 2026 was $-0.43 Mil. Stemtech's Revenue for the three months ended in Mar. 2026 was $0.46 Mil. Therefore, Stemtech's FCF Margin % for the quarter that ended in Mar. 2026 was -92.01%.

As of today, Stemtech's current FCF Yield % is -83.97%.

The historical rank and industry rank for Stemtech's FCF Margin % or its related term are showing as below:

STEK' s FCF Margin % Range Over the Past 10 Years
Min: -44.3   Med: -21.76   Max: -6.36
Current: -8.05

During the past 6 years, the highest FCF Margin % of Stemtech was -6.36%. The lowest was -44.30%. And the median was -21.76%.

STEK's FCF Margin % is ranked worse than
71.29% of 958 companies
in the Drug Manufacturers industry
Industry Median: 2.445 vs STEK: -8.05

Stemtech FCF Margin % Related Terms

Stemtech FCF Margin % Historical Data

* Premium members only.

The historical data trend for Stemtech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stemtech FCF Margin % Chart

Stemtech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -44.30 -26.69 -41.37 -11.89 -16.83

Stemtech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81.91 10.74 2.93 27.73 -92.01

STEK vs PNXP, ZTS, UTHR: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Stemtech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stemtech FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Stemtech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Stemtech's FCF Margin % falls into.


Stemtech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Stemtech's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.484/2.876
=-16.83 %

Stemtech's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.426/0.463
=-92.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -92.01% mean?
Stemtech (STEK) has a FCF Margin % of -92.01% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Stemtech and its competitors. According to the industry distribution chart, Stemtech ranks #683 out of 958 companies in the Drug Manufacturers industry, placing it in the top 71.3%.
Is Stemtech's FCF Margin % too high?
Stemtech's current FCF Margin % is -92.01%. Based on the distribution chart, Stemtech ranks #683 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Stemtech's FCF Margin % compare to PNXP and ZTS?
According to the Drug Manufacturers industry distribution chart, Stemtech ranks #683 out of 958 companies for FCF Margin %. This places Stemtech in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Stemtech and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stemtech's current FCF Margin % is -92.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stemtech stock overvalued right now?
Based on GuruFocus' analysis, Stemtech (STEK) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current FCF Margin % is -92.01%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Stemtech (STEK), the current FCF Margin % is -92.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Stemtech Business Description

Address 4851 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
Stemtech Corp is a nutraceutical company. Its products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood and migrate into tissues, where the stem cells perform their daily function of renewal for optimal health. It markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze. Geographically, it derives a majority of its revenue from Latin America.